Treatment Primer on TNBC

Metastatic triple-negative breast cancer (mTNBC) presents a significant therapeutic challenge due to its aggressive nature and lack of hormone or HER2 targets. The current treatment algorithm emphasizes a personalized approach based on biomarker status, prior therapies, and patient health or clinical trial enrollment when available. Overall, treatment decisions are increasingly guided by molecular profiling and emerging biomarkers to optimize outcomes and balance efficacy with tolerability.